You are here » Home » Companies » Company Overview » Medicamen Biotech Ltd

Medicamen Biotech Ltd.

BSE: 531146 Sector: Health care
NSE: N.A. ISIN Code: INE646B01010
BSE 00:00 | 14 Dec 433.90 -0.25
(-0.06%)
OPEN

460.00

HIGH

460.00

LOW

426.05

NSE 05:30 | 01 Jan Medicamen Biotech Ltd
OPEN 460.00
PREVIOUS CLOSE 434.15
VOLUME 2572
52-Week high 784.40
52-Week low 389.90
P/E 44.19
Mkt Cap.(Rs cr) 508
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 460.00
CLOSE 434.15
VOLUME 2572
52-Week high 784.40
52-Week low 389.90
P/E 44.19
Mkt Cap.(Rs cr) 508
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Medicamen Biotech Ltd. (MEDICAMENBIOTEC) - Chairman Speech

Company chairman speech

Dear Shareholders

IT GIVES ME A PLEASURE TO ADDRESS YOU THROUGH OUR ANNUAL REPORT. I AM QUITE PLEASED TOINFORM YOU THAT YOUR COMPANY HAS SEEN A TREMENDOUS TRANSFORMATION OVER THE PAST TWO YEARS.

Transformation requires a relentless focus in all areas of business. We applied thisfocus to identify the potential growth opportunities. We identified our internalcapabilities and re-strategized our business priorities to seize the opportunity.

Here's what we did:

1. Invested in filing product registrations in our own name rather than usingdistributor's identity. This has given us better visibility and credibility acrossdifferent countries.

2. Established new generic molecules category for lifestyle diseases –cardiovascular cholesterol diabetes and blood pressure

3. Enhanced focus on research and development (R&D) activities. We have establisheda new corporate R&D centre at our Bhiwadi unit which will allows us to innovate.

Today we are at an important inflection point of the business transformation. The newstrategy and identity are implemented to more clearly and evocatively tell theorganisation's story.

Going ahead

We will continue to expand into new markets and achieve 100% exports Utilise ourR&D unit towards exploring newer molecular categories Upgrade our Hardiwar Unit atWHO-Geneva Pre-Qualification levels Actively work on backward integration with ShivalikRasayan Limited our group company I would like to acknowledge the efforts of our 250employees and our key management team for their relentless efforts towards bringing aroundthis transformation. I am also thankful to our shareholders investors bankers and allour stakeholders for their faith and support. We will continue to put our efforts towardsproviding a ordable and qualitative formulations and create newer success milestones.

Best Wishes

Rahul Bishnoi